Tackling Solubility Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tackling Solubility Challenges
Nanosupensions are among the ways formulation scientists seek to address the problem of solubility.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 40-44

References

1. R.O. Williams, A.B. Watts, and D.A. Miller, "Preface" in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), p. v–viii.

2. K.P. O'Donnell and R.O. Williams, "Optimizing the Formulation of Poorly Water- Soluble Drugs," in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), pp. 27–28.

3. FDA, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification (Rockville, MD, Aug. 2000).

4. A.H. Jens-Uwe and R. H. Mueller, Int. J. Nanomedicine 3 (3), 295–310 (2008).

5. H. Chen et al., Drug. Discov. Today 16 (7–8), 354–360 (2011).

6. Alkermes, "NanoCrystal Technology" company information, http://www.alkermes.com/Contract-Services/Technologies/Bioavailability-Enhancement, accessed Feb. 13, 2012.

7. SkyePharma, "2011 Half-Year Results" (London, Aug. 18, 2011).

8. SkyePharma, "Insoluble Drug Delivery Platform" company information, http://www.skyepharma.com/Technology/Oral_Technology/Particle_Engineering_Technologies/Insoluble_Drug_Delivery_Platform/Default.aspx?id=80, accessed Feb. 13, 2012.

9. Aptalis Pharmaceutical Technologies, "Biorise Technology" company information, http://www.aptalispharmaceuticaltechnologies.com/tech_biorise.html, accessed Feb. 13, 2012.

10. B. Trout et al., J. Pharm. Sci. 101 (3), 1178–1188 (2012).

11. P. Van Arnum, Pharm. Technol. 32 (7), 96–98 (2007).

12. P. Van Arnum, Pharm. Technol. 35 (7), 46 (2011).

13. J.Q. Thomassen and P. Holm, presentation at the Nanomedicine and Drug Delivery Symposium (Toronto, Nov. 2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here